Differential Viral Protein Expression in Kaposi's Sarcoma-Associated Herpesvirus-Infected Diseases
The American Journal of Pathology, ISSN: 0002-9440, Vol: 156, Issue: 3, Page: 743-749
2000
- 349Citations
- 68Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations349
- Citation Indexes347
- 347
- CrossRef256
- Policy Citations2
- Policy Citation2
- Captures68
- Readers68
- 52
- 16
Article Description
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is linked to KS, primary effusion lymphomas (PEL), and a subset of multicentric Castleman's disease (MCD). Transcript mapping studies using PEL cell lines have allowed preliminary classification of viral gene expression into constitutive (class I) and inducible (class II/III) categories. To determine whether viral gene expression differs in vivo, we examined tissue sections of KSHV-infected disorders, using specific antibodies against proteins that are representative of the different expression classes of KSHV genes. ORF73/LANA appears to be a surrogate marker for KSHV infection because it is constitutively expressed in vitro and in vivo in all KSHV-infected cells. Expression of vIRF1, vIL6, and PF-8 proteins in the infected B cells of MCD lymph nodes reproduces the expression pattern observed in TPA-stimulated KSHV-infected B-cell lines. In contrast, the protein expression of the inducible viral genes that we tested in KS and PEL biopsies is restricted to PF-8 and vIL6, respectively. The tightly restricted expression of KSHV proteins in vivo differs from the dysregulated expression of inducible KSHV genes in vitro and suggests that viral gene expression in KSHV-infected cell lines does not accurately reflect what occurs in diseased tissues. These differences may be related to either cell-specific or immune restriction of viral replication.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002944010649401; http://dx.doi.org/10.1016/s0002-9440(10)64940-1; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033901248&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/10702388; https://linkinghub.elsevier.com/retrieve/pii/S0002944010649401; http://linkinghub.elsevier.com/retrieve/pii/S0002944010649401; http://api.elsevier.com/content/article/PII:S0002944010649401?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0002944010649401?httpAccept=text/plain; http://dx.doi.org/10.1016/s0002-9440%2810%2964940-1; http://ajp.amjpathol.org/article/S0002-9440(10)64940-1/abstract; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fajp.amjpathol.org%2Farticle%2FS0002-9440%2810%2964940-1%2Fabstract&rc=0&code=ajpa-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fajp.amjpathol.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa9FIZCGMx4Cbj48eVxv%2526MAID%253D2C6fYjDQ5cCf1CS8qJCu8Q%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D864919675%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fajp.amjpathol.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa9FIZCGMx4Cbj48eVxv%2526MAID%253D2C6fYjDQ5cCf1CS8qJCu8Q%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D864919675%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fajp.amjpathol.org%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa9FIZCGMx4Cbj48eVxv%26MAID%3D2C6fYjDQ5cCf1CS8qJCu8Q%253D%253D%26SERVER%3DWZ6myaEXBLGvmNGtLlDx7g%253D%253D%26ORIGIN%3D864919675%26RD%3DRD&acw=be364ab8ec0f5513072fb22%2D436793f874cd7982%257C%2524%257CA522EC3D053258A3AAA692617D66A482982293152E389419B4BDA120A136B44E593AA1DE566D19F0F1DF0E8AE39F8EEBE88BE091101716A5A2F71CEDB4D1441271E44FE464F2306037E61E1E60C5F3ED7161AC1F06C006CBBC57E5516DFE3C34D74FDB647D9EF376626332E0B03FBC3C4AC26B0893EE3888B121B6CA284FCC3A&utt=
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know